[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Retinal Vein Occlusion Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          Type Overview

4.1       Introduction

4.1.1    Market Size & Forecast

4.2       Branch Retinal Artery Occlusion

4.3       Central Retinal Vein Occlusion

5          Condition Overview

5.1       Introduction

5.1.1    Market Size & Forecast

5.2       Non-Ischemic

5.3       Ischemic

6          Diagnosis Overview

6.1       Introduction

6.1.1    Market Size & Forecast

6.2       Optical coherence tomography (OCT)

6.3       Fundoscopic examination

6.4       Fluorescein angiography

6.5       Others

7          Treatment Overview

7.1       Introduction

7.1.1    Market Size & Forecast

7.2       Anti-vascular endothelial growth factor

7.3       Corticosteroid drugs

7.4       Laser retinal photocoagulation

7.5       Others


8          End User Overview

8.1       Introduction

8.1.1    Market Size & Forecast

8.2       Hospitals and clinics

8.3       Research & academics centers

8.4       Others

9          Regional Overview

9.1       Introduction

9.1.1    Market Size & Forecast

9.2       America

9.2.1    North America

9.2.1.1 U.S.

9.2.1.1.1          By Type

9.2.1.1.2          By Condition

9.2.1.1.3          By Diagnosis

9.2.1.1.4          By Treatment

9.2.1.1.5          By End User

9.2.1.2 Canada

9.2.1.2.1          By Type

9.2.1.2.2          By Condition

9.2.1.2.3          By Diagnosis

9.2.1.2.4          By Treatment

9.2.1.2.5          By End User

9.2.1.3 Mexico

9.2.1.3.1          By Type

9.2.1.3.2          By Condition

9.2.1.3.3          By Diagnosis

9.2.1.3.4          By Treatment

9.2.1.3.5          By End User

9.2.2    South America

9.2.2.1             By Type

9.2.2.2             By Condition

9.2.2.3             By Diagnosis

9.2.2.4             By Treatment

9.2.2.5             By End User

9.3       Europe           

9.3.1    Market Size & Forecast (Value)         

9.3.2    Western Europe

9.3.2.1 Germany        

9.3.2.1.1          By Type          

9.3.2.1.2          By Condition   

9.3.2.1.3          By Diagnosis   

9.3.2.1.4          By Treatment

9.3.2.1.5          By End User    

9.3.2.2  France           

9.3.2.2.1          By Type          

9.3.2.2.2          By Condition

9.3.2.2.3          By Diagnosis

9.3.2.2.4          By Treatment

9.3.2.2.5          By End User    

9.3.2.3  U.K.    

9.3.2.3.1          By Type          

9.3.2.3.2          By Condition

9.3.2.3.3          By Diagnosis

9.3.2.3.4          By Treatment

9.3.2.3.5          By End User           

9.3.2.4  Italy   

9.3.2.4.1          By Type          

9.3.2.4.2          By Condition

9.3.2.4.3          By Diagnosis

9.3.2.4.4          By Treatment

9.3.2.4.5          By End User    

9.3.2.5  Spain 

9.3.2.5.1          By Type          

9.3.2.5.2          By Condition

9.3.2.5.3          By Diagnosis

9.3.2.5.4          By Treatment

9.3.2.5.5          By End User    

9.3.2.6  Rest of Western Europe        

9.3.2.6.1          By Type

9.3.2.6.2          By Condition

9.3.2.6.3          By Diagnosis

9.3.2.6.4          By Treatment

9.3.2.6.5          By End User

9.3.3    Eastern Europe

9.4       Asia Pacific    

9.4.1    Market Size & Forecast (Value)         

9.4.2    China  

9.4.2.1            By Type

9.4.2.2            By Condition

9.4.2.3            By Diagnosis

9.4.2.4            By Treatment

9.4.2.5            By End User

9.4.3    India

9.4.3.1            By Type

9.4.3.2            By Condition

9.4.3.3            By Diagnosis

9.4.3.4            By Treatment

9.4.3.5            By End User

9.4.4    Japan  

9.4.4.1            By Type

9.4.4.2            By Condition

9.4.4.3            By Diagnosis

9.4.4.4            By Treatment

9.4.4.5            By End User    

9.4.5    South Korea    

9.4.5.1            By Type

9.4.5.2            By Condition

9.4.5.3            By Diagnosis

9.4.5.4            By Treatment

9.4.5.5            By End User

9.4.6    Australia         

9.4.6.1            By Type

9.4.6.2            By Condition

9.4.6.3            By Diagnosis

9.4.6.4            By Treatment

9.4.6.5            By End User     

9.4.7    Rest of Asia-Pacific    

9.4.7.1             By Type          

9.4.7.2             By Condition

9.4.7.3             By Diagnosis

9.4.7.4             By Treatment

9.4.7.5             By End User    

9.5       Middle East & Africa

9.5.1    Market Size & Forecast (Value)         

9.5.2    The Middle East

9.5.2.1  South Africa

9.5.2.1.1          By Type          

9.5.2.1.2          By Condition

9.5.2.1.3          By Diagnosis

9.5.2.1.4          By Treatment

9.5.2.1.5          By End User

9.5.2.2  UAE

9.5.2.2.1          By Type         

9.5.2.2.2          By Condition

9.5.2.2.3          By Diagnosis

9.5.2.2.4          By Treatment

9.5.2.2.5          By End User           

9.5.2.3  Qatar

9.5.2.3.1          By Type         

9.5.2.3.2          By Condition

9.5.2.3.3          By Diagnosis

9.5.2.3.4          By Treatment

9.5.2.3.5          By End User          

9.5.2.4  Rest of Middle East

9.5.2.4.1          By Type

9.5.2.4 2          By Condition

9.5.2.4 3          By Diagnosis

9.5.2.4 4          By Treatment

9.5.2.4 5          By End User

9.5.3    Africa

9.5.3.1        By Type    

9.5.3.2        By Condition

9.5.3.3        By Diagnosis

9.5.3.4        By Treatment

9.5.3.5        By End User

10.       Company Profile                  

10.1     ALLERGAN

10.1.1  Company Overview   

10.1.2  Financial Performance          

10.1.3  Recent Developments

10.1.4  Product Portfolio        

10.2     Bayer AG

10.2.1  Company Overview   

10.2.2  Financial Performance          

10.2.3  Recent Developments

10.2.4  Product Portfolio        

10.3     Bristol-Myers Squibb Company

10.3.1  Company Overview   

10.3.2  Financial Performance          

10.3.3  Recent Developments

10.3.4  Product Portfolio        

10.4     Regeneron

10.4.1  Company Overview   

10.4.2  Financial Performance          

10.4.3  Recent Developments

10.4.4  Product Portfolio        

10.5     Ellex

10.5.1  Company Overview   

10.5.2  Financial Performance          

10.5.3  Recent Developments

10.5.4  Product Portfolio        

10.6     Novartis AG

10.6.1  Company Overview   

10.6.2  Financial Performance          

10.6.3  Recent Developments

10.6.4  Product Portfolio        

10.7     F. Hoffmann-La Roche Ltd

10.7.1  Company Overview   

10.7.2  Financial Performance          

10.7.3  Recent Developments

10.7.4  Product Portfolio        

10.8     Topcon Corporation

10.8.1  Company Overview   

10.8.2  Financial Performance          

10.8.3  Recent Developments

10.8.4  Product Portfolio        

10.9     IRIDEX Corporation

10.9.1  Company Overview   

10.9.2  Financial Performance          

10.9.3  Recent Developments

10.9.4  Product Portfolio        

10.10   Sanofi

10.10.1  Company Overview 

10.10.2  Financial Performance        

10.10.3  Recent Developments          

10.10.4  Product Portfolio      



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports